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Introduction. The combination of antidepressants is a useful tool in the treatment of major depression, especially in cases where
there is a partial response to antidepressant monotherapy. However, the use of this strategy is a matter of controversy, and its
frequency of use in clinical practice is not clear. The aim of our study is to assess the use of antidepressants combination in Spain
by reviewing three databases used between 1997 and 2001. Methods. Databases pertain to patients who are study subjects of major
depression treatment. These databases are a result of studies performed in Spain and in which 550 psychiatrists participated. The
totalstudiedsamplewascomprisedofN = 2,842patients,agedover18,ﬁttingDSM-IVcriteriaforMajorDepressiveEpisode.The
percentageofpatientswhoreceivedmorethanoneantidepressantandthetypesofcombinationsusedwasdescribed.Subsequently,
a comparative study between the group which received a combination of antidepressants (N = 64) and the group which
received antidepressant monotherapy (N = 775) was performed. Results. 27.1% of patients were on antidepressive monotherapy
treatment, and 2.2% were on combination therapy. In the comparison of patients on combination therapy and monotherapy,
there were signiﬁcant diﬀerences only in episode duration (P = 0.001). The most frequent combinations are SSRIs and tricyclic
antidepressants. The active principle most widely combined is ﬂuoxetine. Conclusions. The prevalence of use of antidepressant
combination therapy is 2.2% of the global sample and 8.3% of treated patients. Other than duration of the depressive episode, no
clinical characteristics exclusive to patients who received combination rather than monotherapy were found. Our study found that
the most frequent combination is SSRIs + TCAs, also being the most studied.
1.Introduction
According to numerous authors [1–5], the combination of
antidepressants is a useful tool in the treatment of major
depression. It is a therapeutic strategy indicated especially
in cases where response to antidepressant monotherapy is
partial [3]. These situations arise regardless of the type of
therapy used. In a review of 102 studies of patients treated
with tricyclic antidepressants (TCAs), results indicated that
on average, 51% of subjects responded favorably [6]. Simi-
larly, in a review of 39 studies of major depression treated
with SSRIs 47% of patients had a suﬃcient response to
treatment. Given that 15% of the general population is
prone to suﬀer a major depression episode at some point
in their life [7], a substantial number of patients may
require a combination of antidepressants to achieve a full
response. However, indications, selection, and use of these
combinations are a matter of debate. Algorithms such as the
Texas Medication Algorithm project (TMAP) [8], Canadian
clinical guidelines [9, 10], Hirschfeld sequencing [11], the
“Sequenced Treatment Alternatives to Relieve Depression”
(STAR∗D) [12, 13], and McIntyre’s algorithm [14] consider
antidepressant combination therapy as second and third
choice, to be applied only alternative monotherapies are2 Depression Research and Treatment
Table 1: General characteristics of the three databases.
Mar Diana Medas
Period of study November 97 Septembert 98 February 01
February 98 January 99 July 01
Objective of the study
Assess eﬃcacy, onset of eﬀect,
and tolerance to mirtazapine
in the treatment of major
depression
Assess the eﬃcacy and
tolerance to mirtazapine in
sleep and anxiety in major
depression
Evaluate the clinical evolution of
depression and somatic
symptoms during the ﬁrst three
months of treatment with
mirtazapine
Number of
psychiatrists 300 150 100
Sample size 1261 877 704
proven ineﬀective. However, other groups, such as the
Spanish Study Group for Combination of Antidepressants
(SGCAD) [15], place it as ﬁrst choice. Evidence-based
medicine including case series [16, 17], open trials [18–
20], and randomized double-blind controlled studies [21–
23] suggest the eﬃcacy of combination therapy for resistant
depression or for rapid treatment. However, as relatively
little remains known about use of this approach, in the last
few years, several authors have called for studies describing
the actual prevalence of combination therapy use through
patient, general population, or physician surveys [24–26]a s
well as prescription studies [27–30].
The objective of our study is to analyze the frequency of
use of combination antidepressants (ADs) versus monother-
apy among patients with major depression in Spain, and
to assess whether there are clinical or other predictors of
the use of combination AD through the review of three
databases corresponding to naturalistic studies performed in
1997, 2000, and 2001.
2.MaterialandMethods
2.1. Databases. Databases from three naturalistic studies
performed by Organon S.A., in which psychiatrists from
public mental health institutions and general hospitals at
three sites across Spain participated between November 1997
and July 2001, were analyzed (see Table 1). The databases
complied with a series of criteria.
(i) Participants met DSM IV criteria for major depres-
sion
(ii) Information was available on any antidepressant
drugs being taken by the patient prior to enrolment
in the study.
(iii) Objectives, design and methodology without bias
eﬀect,suchasnonexclusionofpatientswhoareunder
treatment.
Databases were compiled as baseline information in
the context of studies assessing the eﬃcacy of the antide-
pressant mirtazapine (see Table 1). At baseline, information
was collected on sociodemographic characteristics, AD use,
basic clinical characteristics, and psychiatric history of all
eligible patients undergoing treatment for or diagnosed with
major depression during the study timeframe, regardless of
medication use. All patients provided informed consent, and
ethical approval was obtained from each institution?
2.2. Study Subjects. The studied sample comprised N =
2,842 patients. All subjects included in this analysis were
over the age of 18, ﬁt DSM-IV criteria for major depression
episode, and had a minimum score of 9 in the Hamilton
Depression Rating Scale (HAMD17). Exclusion criteria
included pregnant or breastfeeding women, concomitant
presence of another psychiatric disorder such a bipolar
disorder as the primary diagnosis, any clinically relevant
and/or nonstabilized renal, hepatic, cardiovascular, respi-
ratory, endocrine, or cerebrovascular pathology, as well
as other serious, progressive, incapacitating or high-risk
physical pathologies, and any other anomaly in the patient’s
health which could possibly interfere with the development
of the study.
2.3. Study Variables. Sociodemographic and clinical vari-
ables were evaluated, including age, sex, marital status,
previous history of depression, number of suicide attempts,
characteristics of the current episode, duration of the
episode, stressful life events, and the score on Hamilton’s
Depression Rating Scale (HAMD17).
All drugs which were being taken by each patient at the
start of the study were taken into account, including antide-
pressants, since the study did not exclude treated patients.
2.4. Data Analysis. A database was created by pooling
databases from studies conducted in catchment areas in
Spain,including 550psychiatristswithasampleconsistingof
2,842patients (see Table 2). The percentage of patients who,
at baseline, received more than one antidepressant and the
types of combinations used was described.
Subsequently, a comparative study between the group
which received a combination of antidepressants (N = 64)
and the group which received antidepressant monotherapy
(N = 775) was performed. The Kruskall Wallis and
Mann Whitney tests were applied to continuous quantitative
variables (age, age of onset, Hamilton Scale score), and theDepression Research and Treatment 3
Table 2: Catchement areas and psychiatrists.
Catchment areas Mar Diana Medas
Castilla y Madrid 15.95% 18.46% 14.74%
Galicia y Asturias 13.62% 10.77% 11.58%
Euskadi 12.84% 12.82% 16.84%
Andaluc´ ıa 20.24% 17.95 15.79%
Extremadura — — 3.16%
Canarias 0.78% — —
Levante 11.28% 12.31 10.53%
Catalunya y Baleares 25.29% 27.69% 27.37%
Chi-square test was applied to categorical variables (e.g., sex,
marital status, duration and level of depression, any previous
suicideattempts,andpreviousdepressiveepisodes).Toassess
the prevalence and patterns of use of combination AD
therapy in patients with depression of shorter duration (e.g.,
perhaps more strongly related to severity, speciﬁc symptoms,
or clinical history), we also conducted similar analyses
among patients with episodes of of ≤ 6months duration.
For statistical analysis the SPSS 12.0package was used.
3. Results
The sample of 2,842 patients had mean ± SD age of 47.48 ±
14.50years,67.5%ofthembeingwomen,andapredominant
marital status of married (62.1%).
In Table 3 the clinical characteristics of each database
and the global sample are described. The average age of
onset was 37.34 (±14.53), 49.2% had a history of previous
depressive episodes, 8.5% of patients had attempted suicide,
and 50% presented with precipitating events. The most
frequent duration was of 1 to 6months, and 44.5% were
characterized as being of moderate intensity.
Regarding the treatment being received when the
interview took place, 27.1% were receiving antidepressant
monotherapy, and 2.2% were receiving a combination, while
70.7% were not receiving antidepressant treatment.
Inthecomparisonbetweenpatientsreceivingantidepres-
sant combination therapy and monotherapy (see Tables 4
and 5), there were signiﬁcant diﬀerences only in episode
duration (P = .001) and not in age (P = .072), sex (P = .34),
marital status (P = .058), age of onset (P = .86), suicide
attempts (P = .2 1 ) ,m e a nH a m i l t o nS c a l es c o r e( P = .77), or
level of depression (P = .16).
Though diﬀerences were not signiﬁcant for the overall
scale, the baseline Hamilton’s Scale did show diﬀerences that
the combination therapy group had higher scores for two
items: item 13 (general somatic symptoms) and item 17
(weight loss) (P<. 05 for both; see Table 4).
Finally, the diﬀerent types of combinations used accord-
ing to drug family and active principle (see Table 6)w e r e
analyzed. The most frequent combinations were SSRIs and
tricyclic antidepressants (n = 35cases), followed by SSRIs
and mianserine (4), TCAs with Dual antidepressants (4),
SIRS and Dual antidepressants (4), and two SSRIs (3).
The active principles most commonly combined were
ﬂuoxetine (n = 28 cases), amitryptilyne (22), paroxetine
(17), and clomipramine (14).
Regarding the combination of SSRI + TCA, the most
widely used combination was ﬂuoxetine with amitryptiline,
and the least used citalopram with clomipramine.
4. Discussion
Antidepressants combination treatments have become a
popular method of treating refractory depression, enhancing
therapeutic response in partial responders, and increasing
the likelihood of more rapid response. Works from Nelson
[6], Fava [31], Kelsey [32]a n dS h e l t o n[ 33] support these
strategies. Also, some researchers, Nelson [1], Besson [34],
and Blier [23] have conducted studies using antidepressant
combination from the beginning of the tretament in an
attempt to obtain a more rapid onset of therapeutic action.
The results from Besson et al. [23] provide evidence that
combination therapy from the beginning of treatment
provides superior clinical eﬀectiveness in the treatment of
major depression.
The objectives of this study were to assess the real
prevalence of the use of antidepressant combinations in the
treatment of major depression in our country and analyze
the clinical characteristics of these patients.
Information on the use of combination antidepressant
[35, 36] therapy is limited, and it remains uncertain whether
the practice is widespread, and whether there are clinical
indicators associated with its use. In this Spanish study,
we found that among patients with major depression, the
prevalence of combination therapy use was 8,3%%. The
latter is comparable to rates varying from 1 to 5% reported
in previous surveys conducted among subjects with major
depression [25]. Rates of use were higher among patients
with more persistent (>6months) episodes of depression.
Regardless of whether episodes were of longer or shorter
(≤6months) duration, use of combination therapy was not
related to other clinical characteristics, including previous
depressive episodes, patient sex, and level of depression.
This suggests that ineﬃcacy of monotherapy, rather than
other indicators of clinical complexity, may be the primary
determinant of selection of combination therapy.
In the bibliographic revision, no studies of this kind are
found. There are, however, other indirect methods to study
the use of antidepressant combinations such as surveys and
prescription studies, but the results obtained are all very
diﬀerent.
In the surveys, the results obtained are varied, ranging
from those that do not detect this tendency [35, 36] to those
that do, with diﬀerent results: 1% [24], 2% [37], 5% [25],
and 15% [26].
The second method is based on studying prescriptions
received by patients in medical consultations. Though it is
closer to the primary care reality, sometimes the combi-
nation’s indication is unknown (since the studies aim to
detect polypharmacy), and results are also very varied: 2–5%
[27, 28], 5% [38], 10% [39], and 24-25% [29, 30].4 Depression Research and Treatment
Table 3: Characteristics of each database and the global sample.
MAR DIANA MEDAS GLOBAL
Year of study November 97 Septembert 98 February 01
February 98 January 99 July 01
Number of psychiatrists 300 150 100 550
Sample size 1261 877 704 2842
Mean (sd) Age, years 47.1 ± 14.2 47.5 ± 14.4 48.0 ± 15.0 47.4 ± 14.5
Sex
Women 68.2% 69.2% 66.0% 68.0%
Men 31.8% 30.8% 34.0% 32.0%
Marital status
Unmarried — 16.4% 19.2% 17.6%
Married — 62.7% 61.2% 62.1%
Separated — 11.2% 10.7% 11.0%
Widowed — 9.0% 8.3% 8.8%
Unknown — 0.6% 0.4% 0.5%
Age of onset 37.3 ± 14.5 36.4 ± 15 38.4 ± 13.8 37.3 ± 14.5
Previous suicide attempts (any) 7.8% 8.9% 8.9% 8.5%
Mean number of suicides/patient 0.14 0.15 0.14 0.14
Any previous depressive episode
No 51.1 49.8 51.5 50.8
Yes 48.9 50.2 48.5 49.2
Other previous psychiatric pathologies 15% 27.9% 26.9% 21.7%
Unleashing factors 45.6% 50.4% 57.2% 50.0%
Episode duration (%)
2 weeks 5.2 3.4 — 3.4
2 weeks-1month 22.2 22.2 22.2 22.2
1–6 months 46.6 49.4 47.4 47.6
7–12 months 12.0 11.5 15.3 12.7
Over 1 year 14.0 13.6 15.2 14.2
Level of Depression
Mild (7–17) 20.7 22.3 14.0 19.5
Moderate (18–24) 39.5 50.1 46.5 44.5
Severe (25–52) 39.7 27.6 39.6 36.0
Antidepressants taken
No ADs 69.9 72.1 70.3 70.7
1 AD 27.4 25.8 28.2 27.1
ADs combination 2.7 2.1 1.5 2.2
The second objective was to assess whether there are
some clinical characteristics that predict patient use of
combination AD treatment.
In the analysis of the clinical characteristics of patients
receiving combination of antidepressants, the only diﬀerence
found is that these patients present a disorder of longer
duration. It is not possible to say they are more complex
patients because, although their age is greater, with a greater
numberofpreviousaﬀectiveepisodes,moresuicideattempts
and chronicity of the disorder, results were not statistically
signiﬁcant.
Patients receiving antidepressant combinations are not
diﬀerent from the point of view of intensity of depres-
sive symptoms according to the analysis of global resultsDepression Research and Treatment 5
Table 4: Comparative study of patients on one AD versus patients on AD combination.
One AD AD combination Statistical Signiﬁcance P ≤ .05
Sample size 775 64
Age 51.2 ± 14.35 53.1 ± 12.06 Z =− 1.2 P = .072%
Sex χ2 = 0.91 P = .34
Women 72.7% 69.6%
Men 27.3% 30.4%
Marital status
Unmarried 13.9% 8.6% χ2 = 3.58 P = .058
Married 62.8% 77.1%
Separated 11.5% 5.7%
Widowed 11.8% 8.6%
Unknown 0.6%
Age of onset 39.8 ± 15.1 40.3 ± 14.8 Z =− 0.59 P = .86
Suicide attempts 10.7% 16.5% χ2 = 1.56 P = .21
Number of suicides/patient 0.19 0.36
Previous depressive episodes χ2 = 0.85 P = .35
No 36.4 42.0
Yes 63.6 58.0
Other previous psychiatric disorders 25.0% 20.3%
Unleashing factors 46.7% 56.5%
Duration of episode (%)
2 weeks 1.8 0.0 χ2 = 16.0 P = .001
2 weeks-1 month 14.7 5.9
1–6 months 47.2 38.2
7–12 months 15.5 11.8
over 1 year 20.7 44.1
Hamilton Scale 21.69 21.69 Z = 0.287 P = .77
Level of Depression (%)
Mild 18.5 18.7 χ2 = 3.6 P = .165
Moderate 40.6 50.0
Severe 41.0 31.2
Table 5: Comparative study of Hamilton basal score one AD versus combination.
Hamilton D-17 items One AD Dt Combination dt P ≤ .05
(1) Depressed mood 2.58 .77 2.76 .93 +
(2) Feelings of guilt 1.29 .88 1.24 .91 −
(3) Suicidal ideation 1.14 .96 1.11 1.03 −
(4) Early insomnia 1.49 .65 1.48 .72 −
(5) Middle insomnia 1.09 .63 1.05 .58 −
(6) Late insomnia 1.09 .75 1.08 .67 −
(7) Work and activities 2.37 .85 2.47 .94 −
(8) Retardation 1.06 .85 1.14 .85 −
(9) Agitation 1.14 .86 1.17 .77 −
(10) Psychic anxiety 2.08 .89 2.16 .82 −
(11) Somatic anxiety 1.86 .78 1.89 .76 −
(12) Somatic symptoms (gastrointestinal) 1.05 .64 .89 .65 −
(13) Somatic symptoms general 1.25 .55 1.17 .02 +
(14) Reduced libido 0.91 0.76 1.03 .78 −
(15) Hypochondriasis 1.30 .97 1.25 1.02 −
(16) Insight into illness .31 .50 .19 .39 −
(17) Loss of weight .70 .70 .41 .00 +
Total 22.67 5.91 22.34 5.52 −6 Depression Research and Treatment
from Hamilton’s scale. Results also showed an unexpected
consideration, which was obtaining a nonsigniﬁcant result
in items 10 and 11, which refer to anxiety symptoms,
since depression that progresses with anxiety requires higher
dosage of antidepressants and is often more dependent on
combination therapy [40].
The literature reviewed shows no studies that analyze the
clinical and sociodemographic characteristics of the patient
receiving combined treatment. The revised works tend to
analyze prescription tendencies or perform open trials where
the eﬃcacy of the combination strategy with diﬀerent types
of molecules is demonstrated.
However, some data obtained indirectly from the biblio-
graphic revision can be contrasted with our study.
As such, in clinical characteristics, patients who are
combining antidepressants are deﬁned as more complex due
to their tendency towards chronicity [37]o rt op e r s o n a l i t y
disorder comorbility [41]. These factors are indicators of
combination [42].
Regardingthetypeofaﬀectivedisorder,somestudiesaim
to prove the eﬃcacy of this strategy but highlight certain
characteristics of these patients.
(i) Sethna [43], characterizes the patient who undergoes
this strategy as a patient with a history of aﬀective
disorder of many years, with a tendency towards
chronicity, dominant anxiety symptoms, without
weight loss, early morning waking, or daily variation.
(ii) Seth et al. [16] consider the factors of chronicity and
resistance of the aﬀective disorder as indicators for
the use of this strategy.
(iii) Mancini et al. [44] recommend the combina-
tion of SSRIs and noradrenergic antidepressants in
depressed patients with obsessivoid symptoms.
(iv) Bauer et al. [30] described that patients with more
severedepressionhadagreaterlikelihoodofreceiving
a combination of antidepressant.
The analysis of the antidepressants used shows that the
combinations and drugs found in our study present similar
behavioursexceptforslightdiﬀerences,whencomparedwith
therevisedliterature.The high frequencyofthe combination
of SSRIs and TCAs corresponds to a greater amount of
scientiﬁc articles dealing with this subject. The reasons are
theobviousgreateruseofthesemoleculesandtheprevalence
of depression’s monoaminergic theories in clinical practice,
leadingtothesearchforafullresponsewhentheuseofSSRIs
is accompanied by a partial response.
A more frequent use of ﬂuoxetine is also detected, due to
thefactthatitistheﬁrstSSRIandmostcommonlyused[45].
Ad i ﬀerence is found in the type of TCA used. In our
sample a greater use of amitryptiline is detected, while the
literature shows that the most commonly used antidepres-
sants are desipramine (not commercialized in our country),
clomipramine, and nortriptyline. CAD is recommended
to improve response and side eﬀects (adjuntive therapy).
Amitriptiline election would correspond better with the
second indication.
Table 6: Combinations types.
Combinations types Number
TCA + SSRI 35
TCA + DUAL ADs 4
SSRI + Mianserine 4
SSRI + SSRI 3
SSRI + DUAL ADs 3
TCA + TCA 3
SSRI + Trazodone 2
DUAL ADs + Mianserine 2
SSRI + Nefazodone 1
SSRI + TCAs + Nefazodone 1
D u a lA D s+I N A+T r a z o d o n e 1
SSRI + TCAs + INA 1
SSRI + TCAs(2) 1
SSRI(2) + Dual ADs 1
SSRI(3) + Dual ADs 1
RIMA + Trazodone 1
Total combinations 64
Dual AD:venlafaxine.
INA: Reboxetina.
Certain combinations are rarely advisable, such as the
combination of two SSRIs, with little presence in the litera-
ture [46, 47] or totally inadvisable, such as the combinations
of three and four antidepressants. In these cases, rather than
speaking of combined therapies, the term to use would be
polypharmacy.
Finally, the study of older database might be interpreted
as not representing the current use of antidepressants. It
is true that there are new molecules such as new selective
serotonin reuptake inhibitors (SSRIs), escitalopram, and
dual antidepressants as duloxetine. However, the current
prescription pattern is similar. In our study, we want to
highlight the frequency and how to use combinations of
antidepressants.
The arguments for this is as follows.
(i) The recent history of depression treatment is repeti-
tive and highlights three periods. First, tricyclic and
tetracyclic antidepressants (TCAs) were the ﬁrst-line
treatment choice treatment; in the second, selective
serotonin reuptake inhibitors (SSRIs). Now, we also
use “third generation” antidepressants (venlafaxine,
duloxetine).
(ii) In each of these periods (1965 and 1990), the
combination of antidepressants becomes signiﬁcant,
especially in the decade of 90ss, with the widespread
use of SSRIs [2, 48] when the strategy of combining
ADs became more widely known.
5. Conclusions
The use of the antidepressant combination strategy is an
issue that has been treated in a ﬂuctuating and controversialDepression Research and Treatment 7
manner over the years. There are those who clearly support
its use and those who question it [30].
The controversy heightens when the matter of this
strategy’s real use in clinical practice is posed. Further eﬀorts
to evaluate this strategy are called for [49].
Inthisstudy,amethoddiﬀerentfromthoserevisedinthe
literature is applied, showing a prevalence of use of 2.2% in
the global sample and 8.3% in treated patients.
In the analysis of the study’s patients’ characteristics, no
traits are found to be exclusive of the patient who receives
antidepressant combinations. Therefore, there are no criteria
in the selection of this strategy.
In regards to the type of combinations obtained in our
study, SSRIs + antidepressants represent the most frequent
option and the most studied and cited in the literature
revised from the 90s. The years in which these studies
were performed would also condition the choice of diﬀerent
molecules. This poses another question, since combinations
acquire greater relevance with the appearance of SSRIs:
w h i c hi sb e t t e r ,t oc o m b i n eo ru s ed u a ld r u g s ?
In our opinion, the strategy of combination of antide-
pressants is inﬂuenced by trends or tendencies in pre-
scription patterns. Despite the controversies and limitations
of diﬀerent studies, the combination of antidepressants is
justiﬁed as a second or third option, especially in cases where
response is partial.
The strengths of the study are that the data are repre-
sentative of Spanish territory and oﬀer results about the use
antidepressant therapy in the practice.
Finally, we would like to comment on the limitations
of our study, such as not learning about the psychiatrists
who participated, which could elucidate the characteristics
of the specialists who prescribe combinations, not knowing
thedosageofthedrugsandnotbeingabletodirectlyevaluate
the eﬃcacy of combination on a patient.
Acknowledgments
The authors would like to thank Dr. Jose Mar´ ıa de Pedro
of the Medical Department of Organon for providing the
databases used in this study. They also thank to Dr.Michelle
Mendez for the comments to a previous version of this
manuscript.
References
[ 1 ]J .C .N e l s o n ,C .M .M a z u r e ,M .B .B o w e r s ,a n dP .I .J a t l o w ,
“A preliminary, open study of the combination of ﬂuoxetine
and desipramine for rapid treatment of major depression,”
Archives of General Psychiatry, vol. 48, no. 4, pp. 303–307,
1991.
[2] J. C. Nelson, “Augmentation strategies with serotonergic-
noradrenergic combinations,” Journal of Clinical Psychiatry,
vol. 59, no. 5, pp. 65–69, 1998.
[3] J. E. Kelsey, “Treatment strategies in achieving remission in
major depressive disorder,” Acta Psychiatrica Scandinavica,
Supplement, vol. 106, no. 415, pp. 18–23, 2002.
[4] S. H. Kennedy, S. M. McCann, M. Masellis et al., “Combining
bupropion SR with venlafaxine, paroxetine, or ﬂuoxetine:
a preliminary report on pharmacokinetic, therapeutic, and
sexual dysfunction eﬀects,” Journal of Clinical Psychiatry, vol.
63, no. 3, pp. 181–186, 2002.
[5] N. Hannan, Z. Hamzah, H. O. Akinpeloye, and D. Meagher,
“Venlafaxine-mirtazapine combination in the treatment of
persistent depressive illness,” J o u r n a lo fP s y c h o p h a r m a c o l o g y ,
vol. 21, no. 2, pp. 161–164, 2007.
[6] J.C.Nelson,“Overcomingtreatmentresistanceindepression,”
Journal of Clinical Psychiatry, vol. 59, no. 16, pp. 13–19, 1998.
[7] R.C.Kessler,“SexanddepressionintheNationalComorbidity
Survey.II:cohorteﬀects,”Journal of AﬀectiveDisorders,vol.30,
no. 1, pp. 15–26, 1994.
[8] M. L. Crismon, M. Trivedi, T. A. Pigott et al., “The Texas
medication algorithm project: report of the Texas consensus
conferencepanelonmedicationtreatmentofmajordepressive
disorder,” Journal of Clinical Psychiatry, vol. 60, no. 3, pp. 142–
156, 1999.
[9] Canadian Network for Mood and Anxiety Treatments, “Clin-
ical Guidelines for the treatment of depressive disorders,”
Canadian Journal of Psychiatry, vol. 46, supplement 1, pp. 5S–
90S, 2001.
[10] A. Duhoux, L. Fournier, C. T. Nguyen, P. Roberge, and R.
Beveridge,“Guidelineconcordanceoftreatmentfordepressive
disorders in Canada,” Social Psychiatry and Psychiatric Epi-
demiology, vol. 44, no. 5, pp. 385–392, 2009.
[11] R. M. A. Hirschfeld, S. A. Montgomery, E. Aguglia et al.,
“Partial response and nonresponse to antidepressant therapy:
current approaches and treatment options,” Journal of Clinical
Psychiatry, vol. 63, no. 9, pp. 826–837, 2002.
[12] “Sequenced Treatment and Alternatives to Relieve depres-
sion: A Study Funded by the National Institute of Men-
tal Health,” About treatment options, December 2002,
http://www.edc.gsph.pitt.edu/stard/public/about2.html.
[13] M. Fava, A. J. Rush, M. H. Trivedi et al., “Background and
rationale for the sequenced treatment alternatives to relieve
depression (STAR∗D) study,” Psychiatric Clinics of North
America, vol. 26, no. 2, pp. 457–494, 2003.
[14] R. S. McIntyre, A. M¨ uller, D. A. Mancini, and E. S. Silver,
“What to do if an initial antidepressant fails?” Canadian
Family Physician, vol. 49, pp. 449–457, 2003.
[15] J. De la Gandara, L. Ag¨ u e r a ,J .E .R o j o ,a n dS .R o s ,“ A l g o r i t h m
for the management of depresi´ on based on the antidepressant
combinations proponed by the GEAA Group,” Acta Psychi-
atrica Scandinavica, vol. 112, no. 428, pp. 36–36, 2005.
[16] R. Seth, A. L. Jennings, J. Bindman, J. Phillips, and K.
Bergmann, “Combination treatment with noradrenalin and
serotonin reuptake inhibitors in resistant depression,” British
Journal of Psychiatry, vol. 161, pp. 562–565, 1992.
[17] A. S. Gonul, F. Akdeniz, O. Donat, and S. Vahip, “Selective
serotonin reuptake inhibitors combined with venlafaxine in
depressed patients who had partial response to venlafaxine:
four cases,” Progress in Neuro-Psychopharmacology and Biolog-
ical Psychiatry, vol. 27, no. 5, pp. 889–891, 2003.
[ 1 8 ]J .B .W e i l b u r g ,J .F .R o s e n b a u m ,S .M e l t z e r - B r o d y ,a n dJ .
Shushtari, “Tricyclic augmentation of ﬂuoxetine,” Annals of
Clinical Psychiatry, vol. 3, no. 3, pp. 209–213, 1991.
[19] J. C. Nelson, C. M. Mazure, M. B. Bowers, and P. I. Jatlow,
“A preliminary, open study of the combination of ﬂuoxetine
and desipramine for rapid treatment of major depression,”
Archives of General Psychiatry, vol. 48, no. 4, pp. 303–307,
1991.
[20] F. L` opez-Mu˜ noz, C. ´ Alamo, G. Rubio, P. Garc´ ıa-Garc´ ıa, and
A. Pardo, “Reboxetine combination in treatment-resistant
depression to selective serotonin reuptake inhibitors,” Phar-
macopsychiatry, vol. 40, no. 1, pp. 14–19, 2007.8 Depression Research and Treatment
[21] A. Medhus, S. Heskestad, and L. Tjemsland, “Mianserin
added to tryciclic antidepressant in depressed patients nor
responding to a tricyclic antidepressant alone. A randomized,
placebo controlled, double blind study,” Nordic Journal of
Psychiatry, vol. 48/5, pp. 355–358, 1994.
[ 2 2 ]J .C .N e l s o n ,C .M .M a z u r e ,P .I .J a t l o w ,M .B .B o w e r s ,a n dL .
H. Price, “Combining norepinephrine and serotonin reuptake
inhibition mechanisms for treatment of depression: a double-
blind, randomized study,” Biological Psychiatry, vol. 55, no. 3,
pp. 296–300, 2004.
[23] P. Blier, H. E. Ward, P. Tremblay, L. Laberge, C. H´ ebert, and R.
Bergeron, “Combination of antidepressant medications from
treatment initiation for major depressive disorder: a double-
blind randomized study,” American Journal of Psychiatry, vol.
167, no. 3, pp. 281–288, 2010.
[24] S. Byrne and A. J. Rothschild, “Psychiatrists’ responses to fail-
ure of maintenance therapy with antidepressants,” Psychiatric
Services, vol. 48, no. 6, pp. 835–837, 1997.
[25] S.J.Fredman,M.Fava,A.S.Kienke,C.N.White,A.A.Nieren-
berg, and J. F. Rosenbaum, “Partial response, nonresponse,
and relapse with selective serotonin reuptake inhibitors in
major depression: a survey of current ’next-step’ practices,”
Journal of Clinical Psychiatry, vol. 61, no. 6, pp. 403–408, 2000.
[26] J. De La G´ andara, L. Ag¨ u e r a ,F .F e r r e ,E .R o j o ,a n dS .R o s ,
“Asociacionesdeantidepresivos:resultadosdeunaencuestade
opini´ on de psiquiatras espa˜ noles,” Psiquiatr´ ıa Biol´ ogica, vol. 9,
no. 5, pp. 184–190, 2002.
[27] K. J. Gregor, J. A. Riley, and D. K. Downing, “Concomitant use
of anxiolytics and hypnotics with selective serotonin reuptake
inhibitors,” Clinical Therapeutics, vol. 18, no. 3, pp. 521–527,
1996.
[28] K. J. Gregor, K. Way, C. H. Young, and S. P. James, “Concomi-
tant use of selective serotonin reuptake inhibitors with other
cytochrome P450 2D6 or 3A4 metabolized medications: How
often does it really happen?” Journal of Aﬀective Disorders, vol.
46, no. 1, pp. 59–67, 1997.
[29] J. A. Kotzan, R. Maclean, W. Wade et al., “Prevalence and
patterns of concomitant use of selective serotonin reuptake
inhibitors and other antidepressants in a high-cost polyphar-
macy cohort,” Clinical Therapeutics, vol. 24, no. 2, pp. 237–
248, 2002.
[30] M. Bauer, B. U. Monz, A. L. Montejo et al., “Prescribing
patterns of antidepressants in Europe: results from the Factors
InﬂuencingDepressionEndpointsResearch(FINDER)study,”
European Psychiatry, vol. 23, no. 1, pp. 66–73, 2008.
[31] M. Fava, “Augmentation and combination strategies in
treatment-resistant depression,” Journal of Clinical Psychiatry,
vol. 62, no. 18, pp. 4–11, 2001.
[32] J. E. Kelsey, “Treatment strategies in achieving remission in
major depressive disorder,” Acta Psychiatrica Scandinavica,
Supplement, vol. 106, no. 415, pp. 18–23, 2002.
[33] R. C. Shelton, “The use of antidepressants in novel combina-
tion therapies,” Journal of Clinical Psychiatry,v o l .6 4 ,n o .2 ,p p .
14–18, 2003.
[34] A. Besson, N. Haddjeri, P. Blier, and C. De Montigny, “Eﬀects
of the co-administration of mirtazapine and paroxetine on
serotonergic neurotransmission in the rat brain,” European
Neuropsychopharmacology, vol. 10, no. 3, pp. 177–188, 2000.
[35] S.J.Fredman,M.Fava,A.S.Kienke,C.N.White,A.A.Nieren-
berg, and J. F. Rosenbaum, “Partial response, nonresponse,
and relapse with selective serotonin reuptake inhibitors in
major depression: a survey of current ’next-step’ practices,”
Journal of Clinical Psychiatry, vol. 61, no. 6, pp. 403–408, 2000.
[36] R. W. Lam, D. D. C. Wan, N. L. Cohen, and S. H. Kennedy,
“Combining antidepressants for treatment-resistant depres-
sion: a review,” Journal of Clinical Psychiatry, vol. 63, no. 8,
pp. 685–693, 2002.
[37] S. S. Shergill and C. L. E. Katona, “Pharmacological choices
after one antidepressant fails: a survey of UK psychiatrists,”
Journal of Aﬀective Disorders, vol. 43, no. 1, pp. 19–25, 1997.
[38] P. McManus, A. Mant, P. Mitchell, D. Birkett, and J. Dudley,
“Co-prescribing of SSRIs and TCAs in Australia: how often
does it occur and who is doing it?” British Journal of Clinical
Pharmacology, vol. 51, no. 1, pp. 93–98, 2001.
[39] L. F. Ag¨ uera-Ortiz, S. Gonz´ alez Parra, R. S´ anchez Piedra,
and T. Palomo, “Prescription patterns of older and newer
antidepresants for geriatric depresive out-patientsPatrones de
uso ambulatorio de los antiguos y nuevos antidepresivos
en pacientes geri´ atricos con depresi´ on,” Actas Espanolas de
Psiquiatria, vol. 28, no. 6, pp. 343–352, 2000.
[40] R. T. Joﬀe and A. J. Levitt, “Antidepressant failure: augmenta-
tion or substitution?” Journal of Psychiatry and Neuroscience,
vol. 20, no. 1, pp. 7–9, 1995.
[41] M. B. Nichol, G. L. Stimmel, and S. C. Lange, “Factors
predicting the use of multiple psychotropic medications,”
Journal of Clinical Psychiatry, vol. 56, no. 2, pp. 60–66, 1995.
[ 4 2 ]J .E .R o j o ,S .R o s ,L .A g ¨ uera, J. De La G´ andara, and J. M. De
Pedro, “Combined antidepressants: clinical experience,” Acta
Psychiatrica Scandinavica, Supplement, vol. 112, no. 428, pp.
25–31, 2005.
[43] E. R. Sethna, “A study of refractory cases of depressive illnesses
and their response to combined antidepressant treatment,”
BritishJournalof Psychiatry, vol. 124, no.3, pp. 265–272, 1974.
[44] C. Mancini, M. Van Ameringen, and P. Farvolden, “Does
SSRI augmentation with antidepressants that inﬂuence nora-
drenergic function resolve depression in obsessive-compulsive
disorder?” Journal of Aﬀective Disorders, vol. 68, no. 1, pp. 59–
65, 2002.
[45] A. Ubeda, E. Cardo, N. Sell´ e s ,R .B r o s e t a ,J .L .T r i l l o ,a n dF .
Fern´ andez-Llim´ os,“Antidepressantutilizationinprimarycare
in a Spanish region: impact of generic and reference-based
pricing policy (2000–2004),” Social Psychiatry and Psychiatric
Epidemiology, vol. 42, no. 3, pp. 181–188, 2007.
[ 4 6 ] G .B o n d o l ﬁ ,C .C h a u t e m s ,B .R o c h a t ,G .B e r t s c h y ,a n dP .B a u -
mann, “Non-response to citalopram in depressive patients:
pharmacokinetic and clinical consequences of a ﬂuvoxamine
augmentation,” Psychopharmacology, vol. 128, no. 4, pp. 421–
425, 1996.
[47] G. Bondolﬁ, C. Lissner, M. Kosel, C. B. Eap, and P. Baumann,
“Fluoxetine augmentation in citalopram non-responders:
pharmacokinetic and clinical consequences,” International
Journal of Neuropsychopharmacology, vol. 3, no. 1, pp. 55–60,
2000.
[48] J. D. Amsterdam and M. Hornig-Rohan, “Treatment algo-
rithms in treatment-resistant depression,” Psychiatric Clinics
of North America, vol. 19, no. 2, pp. 371–386, 1996.
[49] A. J. Rush, “Combining antidepressant medications: a good
idea?” American Journal of Psychiatry, vol. 167, no. 3, pp. 241–
243, 2010.